You are currently logged into
POZ Directory - My Account or Log Out
POZ POZ
  • Home
  • Basics
    • Basics
    • Introduction
    • HIV Transmission and Risks
    • HIV Testing
    • HIV Prevention
    • Newly Diagnosed
    • Starting HIV Treatment
    • HIV Medications
    • HIV Drug Assistance Programs
    • HIV and Liver Disease
    • VIH/SIDA en Español
  • News
    • News
    • Newsfeed
    • Treatment News
    • Features
    • Opinions
    • Conferences
    • Slideshows
    • Videos
    • POZ at Home
    • POZ TV
    • POZ Stories
    • POZ 100
    • By Author
    • RSS Links
  • Hot Topics
    • Hot Topics
    • POZ Awards
    • POZ at 25
    • POZ 100
    • Advocacy
    • COVID-19
    • Criminalization
    • Cure
    • Long-Term Survivors
    • Newly Diagnosed
    • PrEP
    • Prevention
    • Undetectable (U=U)
    • Youth
  • Magazine
    • Magazine
    • Current Issue
    • Archives
    • Digital Editions
    • POZ Focus
    • POZ en Español
    • Subscriptions
    • Email Newsletters
  • Blogs
    • Blogs
    • Recent Posts
    • Browse Bloggers
    • RSS Links
  • Community
    • Community
    • POZ Personals
    • POZ Stories
    • POZ 100
    • Community
    • AIDS Is Everyday
    • Forums
    • Polls
    • Surveys
    • Quizzes
    • Ask POZ
    • Services Directory
    • Calendar
    • Jobs
    • Bookstore
  • About Us
    • About Us
    • About Us
    • Masthead
    • Awards
    • Press Releases
    • Advertise
    • Contact Us
  • Facebook
  • Twitter

© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

© 2021 Smart + Strong.
All Rights Reserved.
Terms of use and
Your privacy.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.

Advertisement

Share


Twitter
Facebook
Pinterest
Tumblr
Email

#EACS 2019

Tweet
  • Share

Treatment: Twice-Yearly Therapy?

Gilead’s HIV capsid inhibitor might need dosing only every six months

Studies Shed Light on Anal Precancer Progression

Abnormal anal screening results are common, but they often do not to lead to invasive cancer.

Why Do Some Newer HIV Drugs Cause Weight Gain?

Future research should examine how particular combinations of antiretrovirals contribute to weight gain, according to one expert.

Descovy for PrEP Remains Safe and Effective at 96 weeks

Rates of HIV acquisition were very low among people taking Descovy or Truvada, but Descovy had less effect on kidneys and bones.

Gilead’s HIV Capsid Inhibitor Might Need Dosing Only Every 6 Months

Studies indicate that there is a very low likelihood that people with HIV have preexisting resistance to the medication.

Biktarvy Maintains High Efficacy for Three Years in Clinical Trials

The integrase inhibitor–based HIV regimen was compared with dolutegravir-based regimens.

Advertisement

Stay Logged In?

You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.

You Have Been Logged Out

Click here to log back in.